SPPI - Spectrum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.77
-0.26 (-1.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.03
Open23.99
Bid17.15 x 1100
Ask24.29 x 800
Day's Range23.29 - 24.08
52 Week Range7.12 - 24.20
Volume761,579
Avg. Volume1,529,565
Market Cap2.45B
Beta2.60
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateMar 7, 2017 - Mar 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-18
1y Target Est29.25
Trade prices are not sourced from all markets
  • Investopedia10 days ago

    Top 4 Small-Cap Stocks for 2018

    Looking at growth outlooks and price targets, these four small-cap stocks could be stellar for the second half of 2018.

  • Business Wire21 days ago

    Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed data from the ADVANCE Phase 3 study which showed that ROLONTIS had an absolute risk reduction of severe neutropenia of 8.5 percent (95% CI: 0.2%, 16.2%) versus pegfilgrastim in Cycle 1. New safety data presented today also showed that the adverse events were not significantly different between two treatment arms.

  • MarketWatch23 days ago

    Harry Boxer’s four momentum stocks breaking out

    Here are four stocks in biotech, energy and media that are breaking out on news. Endocyte Inc.(ECYT) had a strong session Tuesday, up 81 cents, or 6%, to $14.45 on 1.4 million shares traded. The biopharmaceutical company, which on Monday was added to the Russell 3000 Index, announced that an image from its Phase 2 prostate cancer study was selected as “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.

  • ACCESSWIRE23 days ago

    Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Spectrum Pharmaceuticals saw its shares rise after a Bloomberg report revealed that the hematology and oncology company may be considering a sale. Shares of Sophiris Bio were bouncing in Tuesday trading after plummeting on Monday when Wall Street learned that a patient had died in the company’s ongoing phase 2b clinical trial for its prostate drug topsalysin. Spectrum Pharmaceuticals, Inc. shares closed up 14.59% on about 6.4 million shares traded yesterday.

  • Here's Why Spectrum Pharmaceuticals Inc. Is Soaring
    Motley Fool24 days ago

    Here's Why Spectrum Pharmaceuticals Inc. Is Soaring

    Shares jump after rumors that the biotech is looking to sell itself. Here's what investors need to know.

  • Benzinga24 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Achieve Life Sciences Inc (NASDAQ: ACHV ) stock was ...

  • ACCESSWIRE24 days ago

    Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.

  • Bloomberg24 days ago

    Spectrum Pharma Is Weighing a Sale

    Spectrum Pharmaceuticals Inc., a U.S. biotech company focused on oncology and hematology, is exploring options including a sale of the business amid takeover interest from other drugmakers, people familiar ...

  • Business Wire25 days ago

    Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29th at 8:30 a.m. EDT/5:30 a.m. PDT to discuss the ROLONTIS Phase 3 ADVANCE study data being presented at Multinational Association of Supportive Care in Cancer (MASCC) 2018 annual meeting. The call will feature a presentation from ADVANCE study lead investigator, Lee S. Schwartzberg, M.D., FACP Professor of Medicine and Division Chief, Hematology Oncology, The University of Tennessee Health Science Center, and Executive Director, UT/West Cancer Center.

  • Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

  • Why Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Is A Financially Healthy Company
    Simply Wall St.last month

    Why Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Is A Financially Healthy Company

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a market capitalization of US$2.06B, rarely draw their attention from the investingRead More...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Tesaro

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / U.S. equities closed in the green on Wednesday, as bond yields rose pushing financial sector higher. The Dow Jones Industrial Average jumped 1.40 percent to close ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference being held at the Grand Hyatt in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • ACCESSWIRE2 months ago

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • Why Spectrum Pharmaceuticals, Inc. Is Up Big Today
    Motley Fool2 months ago

    Why Spectrum Pharmaceuticals, Inc. Is Up Big Today

    Shares jumped after the company shared new details from an important phase 3 study. Here's what investors need to know.

  • Business Wire2 months ago

    CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”). ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed results from ADVANCE, a Phase 3 trial of ROLONTIS, demonstrating that it was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of the study. ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. “These data expand our understanding of the clinical profile of eflapegrastim and help establish it as a possible supportive care treatment option for the multitude of patients undergoing chemotherapy,” said Lee Schwartzberg, M.D., FACP, lead investigator, professor of medicine and division chief, hematology oncology, University of Tennessee Health Science Center, and executive director, UT/West Cancer Center.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2018 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. A live webcast of Spectrum’s presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Spectrum Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE2 months ago

    Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib

    LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.

  • Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
    Zacks3 months ago

    Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1

    Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.

  • Associated Press3 months ago

    Spectrum Pharma: 1Q Earnings Snapshot

    On a per-share basis, the Henderson, Nevada-based company said it had a loss of 16 cents. Losses, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update

    Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended March 31, 2018.

  • Investopedia3 months ago

    Top 4 Small-Cap Stocks for 2018

    Small-cap stocks are considered riskier than large caps or even mid caps. Of course, this means that smaller stocks have greater potential to make profits for investors. This does not mean that you should buy risky stocks randomly.

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of poziotinib. “We have been aggressively pursuing the potential of exon 20 mutations and treatment with poziotinib since the inception of our relationship with MD Anderson, but we’ve both only begun to scratch the surface of the science and poziotinib’s potential as a targeted treatment for various solid tumors,” said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.